Germany’s drug assessment body said data provided by Bayer on the precision cancer drug Vitrakvi did not provide clear enough evidence of benefits, in a setback to the drugmaker in the company’s home market.
Roche Holding AG priced the company’s personalized cancer treatment Rozlytrek at about $17,050 per month, nearly half of the monthly price of a rival drug from Bayer AG and Eli Lilly and Co. that was approved during 2018.
The EMA recommended approving Vitrakvi to tackle tumors with a specific genetic mutation regardless of where the disease started.
Swiss drugmaker Roche’s push into personalized cancer medicines hit a milestone with Japanese approval of a new drug, Rozlytrek, that targets patients who must be identified via genetic profiling.
